CSI Market
Sign In | Register

Newamsterdam Pharma N v (NAMS) Annual Balance Sheets

Annual · GAAP · USD millions
Access NAMS quarterly Balance Sheets →
A period-by-period view of the balance sheet from Newamsterdam Pharma N v to helps clarify how Dec 31 2025's financial structure has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022)
Assets
Cash & cash equivalent490.00
Marketable Securities, Current SH146.24
Cash & Short-term Investments636.00
Other Receivables6.77
Notes Receivable, Current0.23
Other Current Assets1.32
Prepaid Expense And Other Assets Current1.84
Total Current Assets675.70
Equipment/Property/Plant Net0.38
Intangible Assets0.41
Long-term investments92.61
Tax Assets, Noncurrent217.05
Prepaid Expense, Noncurrent, Total PR0.00
Other Assets, Noncurrent92.61
Employee Receivables Current0.00
Restricted Cash Current1.32
Non Current Prepaid Expenses-
Noncurrent Assets-
Current Prepayments And Other Receivables-
Non Current Prepaid Expenses-
Noncurrent Assets-
Current Prepayments And Other Receivables-
Operating Lease Right Of Use Asset0.19
Total Assets769.28
Liabilities
Accounts Payable, Current AC15.42
Accrued Liabilities, Current9.36
Derivative Liability, Current DE57.27
Other Liabilities, Current15.56
Deferred Revenue, Current DE3.99
Total Current Liabilities85.79
Total Long-term Debt0.00
Derivative Liability, Noncurrent DE0.00
Deferred Revenue, Noncurrent DE0.00
Other liabilities, Noncurrent0.00
Operating Lease Liability Current0.14
Operating Lease Liability Noncurrent0.07
Total Liabilities85.85
Stockholders' Equity
Common Stock Value14.28
Additional Paid In Capital Common Stock1,426.75
Retained Earnings / Accumulated Deficit-762.39
Accumulated Other Comprehensive Income4.79
Other Equity4.79
Common Stockholder's Equity683.43
Total Stockholder's Equity683.43
Liabilities & Stockholder's Equity769.28
4 historic quarters locked

Sign in to unlock the full Newamsterdam Pharma N v balance sheet history.

Sign In Create Free Account

About Newamsterdam Pharma Co N v Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 18, 2026
  • Source: nams-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-056029

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License